SYRE vs. SRPT, KRYS, ACAD, SWTX, ZLAB, RARE, ACLX, ALVO, PTGX, and CPRX
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Sarepta Therapeutics (SRPT), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Alvotech (ALVO), Protagonist Therapeutics (PTGX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs. Its Competitors
Spyre Therapeutics (NASDAQ:SYRE) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Sarepta Therapeutics received 1461 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 75.01% of users gave Sarepta Therapeutics an outperform vote.
Sarepta Therapeutics has a net margin of 7.43% compared to Spyre Therapeutics' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat Spyre Therapeutics' return on equity.
Spyre Therapeutics currently has a consensus target price of $53.40, suggesting a potential upside of 201.52%. Sarepta Therapeutics has a consensus target price of $122.61, suggesting a potential upside of 228.62%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Spyre Therapeutics.
80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Spyre Therapeutics has a beta of 2.72, indicating that its stock price is 172% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Spyre Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sarepta Therapeutics had 15 more articles in the media than Spyre Therapeutics. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 4 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.12 beat Sarepta Therapeutics' score of 0.55 indicating that Spyre Therapeutics is being referred to more favorably in the media.
Summary
Sarepta Therapeutics beats Spyre Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy SYRE Stock Free SYRE Stock Alerts